Collaboration, License and Option Agreements - Summary of Contract Assets and Liabilities (Details) $ in Thousands |
6 Months Ended |
|---|---|
|
Jun. 30, 2026
USD ($)
| |
| Deferred revenue | |
| Deferred revenue as of beginning of period | $ 60,658 |
| Additions | 6,000 |
| Collaboration and license revenue recognized | (31,340) |
| Deferred revenue as of end of period | 35,318 |
| Collaboration and Stock Purchase Agreement | AbbVie | |
| Deferred revenue | |
| Deferred revenue as of beginning of period | 34,007 |
| Additions | 6,000 |
| Collaboration and license revenue recognized | (20,726) |
| Deferred revenue as of end of period | 19,281 |
| License and Stock Purchase Agreement | Gilead | |
| Deferred revenue | |
| Deferred revenue as of beginning of period | 26,651 |
| Collaboration and license revenue recognized | (10,614) |
| Deferred revenue as of end of period | $ 16,037 |